The US Justice Department is looking into the prices of skin treatments made by Perrigo and some other companies as part of a broad criminal investigation into possible collusion in the generic drug industry, reported Bloomberg.
In civil suits brought on behalf of customers allegedly overcharged by generic drug companies, prosecutors asked to delay the exchange of evidence known as discovery to avoid compromising the government's ongoing investigation.
The letter refers to lawsuits about three skin drugs whose manufacturers include Perrigo, Akorn, Taro Pharmaceutical, Novartis' Sandoz unit, Wockhardt and Teva. However, the Justice Department did not say those companies are targets of the investigation.
The letter, filed in federal court in Manhattan, asks a judge to pause discovery against generic-drug manufacturers over claims they fixed prices for fluocinonide, desonide and clobetasol, which treat skin disorders like eczema and psoriasis.
"There are significant overlaps between the companies and drugs that are being investigated criminally and the defendants and drugs identified in plaintiffs' amended complaints," the Justice Department said.
Perrigo, which along with the other companies said it will seek to dismiss the civil complaints, declined to comment on any government probe.
To read more NewsPoints articles, click here.